Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...

This study demonstrates a previously unknown, potent effect of PDE5A inhibition in suppressing chamber, cellular and molecular remodeling while improving cardiac function in hearts exposed to ...